<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232971</url>
  </required_header>
  <id_info>
    <org_study_id>GluST1_2014</org_study_id>
    <secondary_id>2014-002267-15</secondary_id>
    <secondary_id>H-1-2014-041</secondary_id>
    <nct_id>NCT02232971</nct_id>
  </id_info>
  <brief_title>Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes</brief_title>
  <acronym>GluST1</acronym>
  <official_title>Treatment of Hypoglycemia With Glucagon Among Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Novo Nordic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Patients with type 1 diabetes (T1D) need a lifelong supply of external insulin
      and are advised to aim for near-normalization of blood glucose levels through intensive
      insulin therapy. We propose a new approach for achieving treatment goals in T1D: the combined
      use of insulin and glucagon, i.e. dual-hormone treatment.Only recently the prospect of
      treating patients with soluble glucagon has arisen and thus studies of low dose glucagon
      treatment of mild hypoglycemia are needed to determine whether there is clinical rationale
      for dual-hormone treatment of T1D.

      Aim: The purpose of this clinical study is to investigate the glycemic response to
      subcutaneous glucagon administration during mild hypoglycemia in T1D patients treated with
      insulin pump. Different glucagon doses are applied to determine the most appropriate dose for
      future dual-hormone treatment of T1D.

      Methods: A clinical, randomized, single blinded, crossover study will be conducted. Eight T1D
      patients treated with insulin pump are studied on four days. All patients are in good
      metabolic control (HbA1c &lt; 7.5%), C-peptide negative and with hypoglycemia awareness. On each
      study day, hypoglycemia is induced with subcutaneously insulin and afterward treated with a
      single subcutaneous dose of glucagon. The study procedures are identical on all days except
      from the administered dose of glucagon (day 1: placebo, day 2: 100 ug, day 3: 200 ug, day 4:
      300 ug). All patients are blinded for the glucagon dose and carry out the four days in random
      order.

      Endpoints: The present study focuses primarily on the dose related plasma glucose response of
      glucagon; secondary on the duration of the hyperglycemic effect of glucagon and tertiary the
      glucagon effect on catecholamine, cortisol, growth hormone, free fatty acids and
      triglycerides.

      The study will be conducted from august 2014.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma glucose response</measure>
    <time_frame>Plasma glucose measured every five minutes after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hyperglycemic effect of glucagon</measure>
    <time_frame>Plasma glucose is measured every five minutes. Time period is two -three hours after glucagon administration</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma Catecholamine</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma free fatty acids</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Beta-Hydroxybutyric acid</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Glucagon</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Growth hormone</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Cortisol</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Insulin (Novorapid)</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse reaction: Stomach pain</measure>
    <time_frame>One time before and after insulin administration. One time before glucagon administration. After glucagon administration at T=15 min., T=60 min., T=120 min., T=240 min.</time_frame>
    <description>Visual analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse reaction: Headache</measure>
    <time_frame>One time before and after insulin administration. One time before glucagon administration. After glucagon administration at T=15 min., T=60 min., T=120 min., T=240 min.</time_frame>
    <description>Visual Analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Reaction: Vertigo</measure>
    <time_frame>One time before and after insulin administration. One time before glucagon administration. After glucagon administration at T=15 min., T=60 min., T=120 min., T=240 min.</time_frame>
    <description>Visual analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse reaction: Nausea</measure>
    <time_frame>One time before and after insulin administration. One time before glucagon administration. After glucagon administration at T=15 min., T=60 min., T=120 min., T=240 min.</time_frame>
    <description>Visual analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse reaction: Hunger</measure>
    <time_frame>One time before and after insulin administration. One time before glucagon administration. After glucagon administration at T=15 min., T=60 min., T=120 min., T=240 min.</time_frame>
    <description>Visual analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma triglycerides</measure>
    <time_frame>Measured at 0, 5, 10, 15, 30, 45, 60, 90, 120,180, 240 minutes after glucagon administration</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isotonic Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GlucaGen(r) 0.1 mg administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GlucaGen(r) 0.2 mg administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon 0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GlucaGen(r) 0.3 mg administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Glucagon is given in three different doses according to three research days.</description>
    <arm_group_label>Glucagon 0.1 mg</arm_group_label>
    <arm_group_label>Glucagon 0.2 mg</arm_group_label>
    <arm_group_label>Glucagon 0.3 mg</arm_group_label>
    <other_name>GlucaGen (r)</other_name>
    <other_name>Disp. no. 2514</other_name>
    <other_name>Novo Nordisk A/S</other_name>
    <other_name>Novo Allé</other_name>
    <other_name>2880 Bagsværd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isotonic saline solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Natriumklorid isotonisk &quot;SAD&quot;</other_name>
    <other_name>D.sp.no. 6733</other_name>
    <other_name>Amgros I/S</other_name>
    <other_name>Dampfærgevej 22</other_name>
    <other_name>Postbox 2593</other_name>
    <other_name>2100 København Ø</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18-65 years

          -  Diagnosed with type 1 diabetes &gt; 3 years

          -  HbA1c &lt; 58 mmol/mol

          -  No appearance of autonome neuropathy

          -  Body mass index (BMI) between 20-25 kg/m2

          -  Remained hypoglycemic awareness

          -  Insulin pump treatment &gt; 1 year

        Exclusion Criteria:

          -  Allergic to glucagon or lactose

          -  Pregnancy, breast-feeding, intention of becoming pregnant, or not using adequate
             contraception

          -  Any disease or condition which would interfere with the subject's safety

          -  Use of a medication that significantly impacts glucose metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajenthen Ranjan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Signe Schmidt, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirsten Nørgaard, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sten Madsbad, Prof, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens J Holst, Prof, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Ajenthen Ranjan</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>glucagon</keyword>
  <keyword>insulin pump</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>closed-loop</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

